Gulati S, Crist M, Riaz MK, Takiar V, et al. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial. Clin Cancer Res 2023 Feb 21:CCR-22-3886. doi: 10.1158/1078-0432.CCR-22-3886.
PMID: 36802410